Physicians' Academy for Cardiovascular Education

Heart Failure

Follow the news, literature, and elearning on new developments in the management of Heart Failure.

Novel potassium binders to improve management of chronic HF

10' education - Oct. 21, 2020 - Prof. Javed Butler, MD

Understanding risk of hyperkalemia in heart failure

10' education - Oct. 8, 2020 - Prof. Piotr Ponikowski, MD, PhD

Heart failure, a multimorbid syndrome: An increasing challenge to manage

10' education - Sep. 21, 2020 - Prof. Carolyn Lam, MD, PhD

New potassium binders for management of hyperkalemia in HF

10' education - Sep. 16, 2020 - Prof. Faiez Zannad, MD

Setting a patient on the right track following hospitalization for ADHF

15' education - Sep. 14, 2020 - Alexander Cadenbach, MD and prof. Mark Petrie, MD - Online CME

Iron deficiency in patients with heart failure

10' education - Sep. 8, 2020 - Niels Grote Beverborg, MD, PhD

Incredible consistency between two SGLT2i trials in HFrEF

3' education - Sep. 7, 2020 - Milton Packer, MD

How to diagnose and treat amyloidosis?

10' education - Sep. 1, 2020 - Prof. Peter van der Meer, MD, PhD

SGLT2 inhibitors: a new foundation in heart failure or another diuretic?

10' education - Sep. 1, 2020 - Prof. Rudolf de Boer, MD, PhD

Succes with SGLT2 inhibitor in HFrEF for all three end points

3' education - Aug. 29, 2020 - Milton Packer, MD

Remarkably similar findings with another SGLT2i in HFrEF

3' education - Aug. 29, 2020 - Prof. John McMurray

How will outcomes of ARNI trials impact diagnosis and management of HF?

10' education - Aug. 26, 2020 - Prof. Mark Petrie, MD

3rd Groningen Heart failure symposium: How to implement the newest HF therapies?

10' education - Aug. 25, 2020 - Prof. Dirk Jan van Veldhuisen, MD and prof. Adriaan Voors, MD

Getting better at diagnosing HFpEF - sharing clinical practice experience

15' education - July 28, 2020 - Prof. Mark Petrie, MD and Pardeep Jhund, MD, PhD - Online CME

Improving outcomes for patients following an admission with ADHF

15' education - July 7, 2020 - Prof. Mark Petrie, MD and Klaus Witte, MD - Online CME

Diabetes and CKD: is it all about managing glucose?

10' education - July 1, 2020 - Prof. Melanie Davies, MD
Lecture 1 out of 3

COVID-19, ACE2 and RAASi - a scientific perspective

10' education - Apr. 19, 2020 - Prof. Jan Danser, PhD
Lecture 2 out of 3

A clinical perspective on COVID-19, ACE2 and RAAS inhibition

10' education - Apr. 18, 2020 - Prof. Murray Epstein, MD
Lecture (panel discussion) 3 out of 3

COVID-19, ACE2 and RAAS inhibition: What are the implications for practice?

10' education - Apr. 17, 2020 - Profs. John Deanfield, Jan Danser and Murray Epstein

Use of ARNI in HFpEF patients reduces NT-proBNP levels

3' education - Apr. 8, 2020 - Jonathan Cunningham, MD

Added value of sGC stimulator in worsening HFrEF patients

3' education - Mar. 31, 2020 - Prof. Paul Armstrong, MD - ACC 2020

HFpEF: A misunderstood disease in search of a therapy

10' education - Jan. 23, 2020 - Prof. Scott Solomon

Effects of ARNI treatment on arterial hemodynamics, cardiac remodelling and pulmonary artery pressure in HFrEF

5' education - Jan. 14, 2020 - Akshay S. Desai, MD

Heart failure with mid-range ejection fraction

10' education - Jan. 6, 2020 - Prof. Burkert Pieske, MD

Efficacy and safety of ARNI in high-risk patients in the PIONEER-HF trial

5' education - Dec. 19, 2019 - Prof. David Morrow, MD

PARADIGM-HF and PARAGON-HF: Redefining HFrEF and HFpEF

10' education - Dec. 10, 2019 - Milton Packer, MD

Is HF the same disease across the EF spectrum, or does HF have two physiologies that respond differently to treatment?

3' education - Nov. 18, 2019 - Prof. Lynne Stevenson - AHA 2019, Philadelphia

ARNI seems to give CV benefit not only in HFrEF, but up to EF of about 60%

3' education - Nov. 18, 2019 - Prof. Scott Solomon - AHA 2019, Philadelphia

Consistent CV benefit and tolerability of SGLT2i in HF patients irrespective of diabetes

3' education - Nov. 16, 2019 - John McMurray, MD, Glasgow - AHA 2019, Philadelphia

Betablocker use associated with reduced mortality in HFrEF patients >80 years

5' education - Oct. 22, 2019 - Paris, France - Gianluigi Savarese, MD

E-learning Heart Failure Practical Tutorials

EBAC-accredited E-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

This series consists of three case discussions on practical challenges in the management of patients with heart failure. The discussions are moderated by prof. Mark Petrie, Glasgow, UK.

Novel potassium binders to improve management of chronic HF

10' education - Oct. 21, 2020 - Prof. Javed Butler, MD
RAAS inhibitors can cause hyperkalemia in HF patients. Javed Butler explains how novel potassium binders may improve management of patients with chronic HF by continuation of RAASi.

RAAS inhibitors can cause hyperkalemia in HF patients leading to RAASi downtitration or discontinuation. Novel potassium binders may improve management of HF patients by continuation of RAASi.

Similar association between CV risk factors and biomarkers with incident HF in men and women

Literature - Oct. 20, 2020 - Suthahar N, et al. - J Am Coll Cardiol. 2020

HF biomarkers and CV risk factors were strongly associated with incident HF without any sex-related differences among women and men.

Primary endpoint just missed for IV ferric carboxymaltose in acute HF

News - Oct. 20, 2020

In the AFFIRM-AHF trial, the primary endpoint was just missed. The trial evaluated the effect of intravenous ferric carboxymaltose compared to placebo on HF hospitalizations and CV death in acute HF patients with iron deficiency.

Understanding risk of hyperkalemia in heart failure

10' education - Oct. 8, 2020 - Prof. Piotr Ponikowski, MD, PhD
Prof. Ponikowski discusses the importance of optimization of RAASi treatment through long-term potassium control in HF patients.

Prof. Ponikowski discusses the importance of optimization of RAASi treatment through long-term potassium control in HF patients with hyperkalemia.

ARNI reduces outcomes irrespective of HF history or ACEi/ARB use in HFrEF after ADHF

Literature - Oct. 5, 2020 - Ambrosy AP, et al. - J Am Cardiol Coll 2020

A subanalysis of the PIONEER-HF trial showed that sacubitril/valsartan lowered NT-proBNP and clinical outcomes compared to enalapril, irrespective of HF history or ACEi/ARB treatment status.

SGLT2 inhibitor improves CV outcomes in HFrEF patients independent of SBP

Literature - Sep. 28, 2020 - Serenelli M et al. - Eur Heart J

In a subanalysis of the DAPA-HF study, dapagliflozin improved CV outcomes in HFrEF patients when compared to placebo, irrespective of baseline SBP.

Heart failure, a multimorbid syndrome: An increasing challenge to manage

10' education - Sep. 21, 2020 - Prof. Carolyn Lam, MD, PhD
Prof. Lam discusses important effects of comorbidities in HF patients and how these comorbidities may affect the use of treatments for HF.

Prof. Lam discusses important effects of comorbidities in HF patients and how these comorbidities may affect the use of treatments for HF.

New potassium binders for management of hyperkalemia in HF

10' education - Sep. 16, 2020 - Prof. Faiez Zannad, MD
Hyperkalemia drives suboptimal use of RAASi therapy, which is associated with increased CV risk in HF patients. Prof. Zannad presents trial results with the new potassium binders ZS-9 and patiromer.

Hyperkalemia drives suboptimal use of RAASi therapy, which is associated with increased CV risk in HF patients. Prof. Zannad presents trial results with the new potassium binders ZS-9 and patiromer.

ARNI reduces adverse renal events and slows kidney function decline in HFpEF patients

Literature - Sep. 15, 2020 - Mc Causland FR et al. - Circulation. 2020

This substudy of the PARAGON-HF trial demonstrated that in HFpEF patients, sacubitril/valsartan reduced the risk of a composite of renal outcomes and attenuated decline in kidney function compared to valsartan alone.

Setting a patient on the right track following hospitalization for ADHF

15' education - Sep. 14, 2020 - Alexander Cadenbach, MD and prof. Mark Petrie, MD - Online CME
Two cardiologists, one in an ambulatory setting and one in a hospital setting, discuss the treatment of a severe heart failure patient following an MI over the course of two years.

Two cardiologists, one in an ambulatory setting and one in a hospital setting, discuss the treatment of a severe heart failure patient following an MI over the course of two years.

Pupil area predicts all-cause mortality and readmission due to HF in HF patients

Literature - Sep. 8, 2020 - Nozaki K et al. - ESC Heart Fail. 2020

A large pupil area in patients admitted with acute HF was significantly associated with a lower all cause mortality and hospital readmission due to HF compared to a small pupil area.